NO20083425L - Ravsyre salt av bifenyl-2-ylkarbaminsyre 1-[2-(2-kloro-4-{[(R)-2-hydroksy-2-(8-hydroksy-2-okso-1,2-dihydroquinolin-5-yl)etylamino]metyl]}-5-metoksyfenylkarbamoyl)etyl]piperidin-4-yl ester og dens anvendelse for behandling av lungesykdom - Google Patents

Ravsyre salt av bifenyl-2-ylkarbaminsyre 1-[2-(2-kloro-4-{[(R)-2-hydroksy-2-(8-hydroksy-2-okso-1,2-dihydroquinolin-5-yl)etylamino]metyl]}-5-metoksyfenylkarbamoyl)etyl]piperidin-4-yl ester og dens anvendelse for behandling av lungesykdom

Info

Publication number
NO20083425L
NO20083425L NO20083425A NO20083425A NO20083425L NO 20083425 L NO20083425 L NO 20083425L NO 20083425 A NO20083425 A NO 20083425A NO 20083425 A NO20083425 A NO 20083425A NO 20083425 L NO20083425 L NO 20083425L
Authority
NO
Norway
Prior art keywords
hydroxy
methoxyphenylcarbamoyl
dihydroquinolin
piperidin
ethylamino
Prior art date
Application number
NO20083425A
Other languages
English (en)
Other versions
NO341343B1 (no
Inventor
Reshma Chudasama
Andrew Kennedy
Leanda Jane Kindon
Franck Patrick Mallett
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36119909&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083425(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20083425L publication Critical patent/NO20083425L/no
Publication of NO341343B1 publication Critical patent/NO341343B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Et ravsyresalt av bifenyl-2-ylkarbaminsyre 1-[2-(2-klor-4-{[(R)-2-hydroksy-2-(8-hydroksy-2-okso-1,2-dihydrokinolin-5-yl)etylamino]metyl}-5-metoksyfenylkarbamoyl)etyl]piperidin-4-ylester eller et solvat derav for anvendelse i behandling av lungesykdommer. 1
NO20083425A 2006-02-10 2008-08-05 Ravsyresalt av bifenyl-2-ylkarbaminsyre 1-[2-(2-klor-4-{[(R)-2-hydroksy-2-(8-hydroksy-2-okso-1,2-dihydrokinolin-5-yl)etylamino]metyl]}-5- metoksyfenylkarbamoyl)etyl]piperidin-4-yl-ester, farmasøytisk preparat som omfatter ravsyresaltet, dets anvendelse, fremgangsmåte for fremstilling derav samt kombinasjon derav med et antiinflammatorisk middel NO341343B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0602778.3A GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound
PCT/EP2007/051196 WO2007090859A1 (en) 2006-02-10 2007-02-08 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{ [ (r)-2-hydroxy-2- (8-hydroxy-2-oxo-1, 2-dihydroquinolin-5-yl) eth ylaminoimethyl] } -5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders

Publications (2)

Publication Number Publication Date
NO20083425L true NO20083425L (no) 2008-09-09
NO341343B1 NO341343B1 (no) 2017-10-16

Family

ID=36119909

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083425A NO341343B1 (no) 2006-02-10 2008-08-05 Ravsyresalt av bifenyl-2-ylkarbaminsyre 1-[2-(2-klor-4-{[(R)-2-hydroksy-2-(8-hydroksy-2-okso-1,2-dihydrokinolin-5-yl)etylamino]metyl]}-5- metoksyfenylkarbamoyl)etyl]piperidin-4-yl-ester, farmasøytisk preparat som omfatter ravsyresaltet, dets anvendelse, fremgangsmåte for fremstilling derav samt kombinasjon derav med et antiinflammatorisk middel

Country Status (33)

Country Link
US (1) US7960551B2 (no)
EP (1) EP1981872B1 (no)
JP (1) JP5616021B2 (no)
KR (1) KR101488691B1 (no)
CN (1) CN101379057B (no)
AR (2) AR059409A1 (no)
AU (1) AU2007213767B2 (no)
BR (1) BRPI0707559B8 (no)
CA (1) CA2641769C (no)
CR (1) CR10227A (no)
CY (1) CY1119238T1 (no)
DK (1) DK1981872T3 (no)
EA (1) EA016580B1 (no)
ES (1) ES2640226T3 (no)
GB (1) GB0602778D0 (no)
HR (1) HRP20171304T1 (no)
HU (1) HUE034315T2 (no)
IL (1) IL193103A (no)
JO (1) JO3389B1 (no)
LT (1) LT1981872T (no)
MA (1) MA30273B1 (no)
MY (1) MY153656A (no)
NO (1) NO341343B1 (no)
NZ (1) NZ570242A (no)
PE (2) PE20071249A1 (no)
PL (1) PL1981872T3 (no)
PT (1) PT1981872T (no)
SG (1) SG169404A1 (no)
SI (1) SI1981872T1 (no)
TW (1) TWI401251B (no)
UA (1) UA100364C2 (no)
WO (1) WO2007090859A1 (no)
ZA (1) ZA200806782B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519138B2 (en) 2009-04-14 2013-08-27 Glaxo Group Limited Process for the preparation of a biphenyl-2-yl carbamic acid ester
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PL3210981T3 (pl) * 2009-04-23 2019-06-28 Theravance Respiratory Company, Llc Związki diamidowe wykazujące działanie jako antagonista receptora muskarynowego i agonista antagonista receptora beta 2 adrenergicznego
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
EA026453B1 (ru) * 2011-08-02 2017-04-28 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Применение окисленного авидина для ингаляции
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
BR112015013628A2 (pt) * 2012-12-18 2017-07-11 Almirall Sa derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022776A (en) 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4894219A (en) 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
EP0972773A1 (en) 1992-03-31 2000-01-19 Glaxo Group Limited 2-Oxadiazolyl- or 2-thiadiazolyl-phenylcarbamate and -phenylurea derivatives, their preparation and their use as intermediates
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
CA2182568A1 (en) 1994-02-10 1995-08-17 Makoto Takeuchi Novel carbamate derivative and medicinal composition containing the same
EP0863141B1 (en) 1995-10-13 2001-09-12 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
CA2313125A1 (en) 1997-12-12 1999-06-24 Laramie Mary Gaster Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
EP1086066A4 (en) 1998-06-08 2001-08-08 Advanced Medicine Inc MUSCARINIC RECEPTOR ANTAGONISTS
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
DE60021282T2 (de) 1999-12-07 2006-05-18 Theravance, Inc., South San Francisco Carbamat-derivate als muscarin-rezeptor antonisten
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
CA2411351A1 (en) 2000-06-05 2001-12-13 Altana Pharma Ag Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
JP2005529111A (ja) 2002-04-12 2005-09-29 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト β模倣薬と新規な抗コリンエステラーゼ剤を含む薬剤
EP1507754A1 (en) 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089892A2 (en) 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
JP4616264B2 (ja) 2003-05-28 2011-01-19 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとしてのアザビシクロアルカン化合物
JP4851937B2 (ja) 2003-11-21 2012-01-11 セラヴァンス， インコーポレーテッド β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
US7320990B2 (en) 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
US7528253B2 (en) 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound

Also Published As

Publication number Publication date
NO341343B1 (no) 2017-10-16
CR10227A (es) 2008-10-29
KR20080114723A (ko) 2008-12-31
US7960551B2 (en) 2011-06-14
JP2009526018A (ja) 2009-07-16
AU2007213767A1 (en) 2007-08-16
NZ570242A (en) 2011-09-30
AU2007213767B2 (en) 2012-04-26
TWI401251B (zh) 2013-07-11
BRPI0707559B8 (pt) 2021-05-25
BRPI0707559A8 (pt) 2019-01-29
MA30273B1 (fr) 2009-03-02
BRPI0707559A2 (pt) 2011-05-10
SI1981872T1 (sl) 2017-10-30
GB0602778D0 (en) 2006-03-22
UA100364C2 (xx) 2012-12-25
EP1981872A1 (en) 2008-10-22
PL1981872T3 (pl) 2017-11-30
PT1981872T (pt) 2017-09-13
MY153656A (en) 2015-03-13
ES2640226T3 (es) 2017-11-02
SG169404A1 (en) 2011-03-30
EA200801691A1 (ru) 2009-02-27
HRP20171304T1 (hr) 2017-10-20
CY1119238T1 (el) 2018-02-14
ZA200806782B (en) 2009-10-28
BRPI0707559B1 (pt) 2021-01-12
HUE034315T2 (en) 2018-02-28
EA016580B1 (ru) 2012-06-29
AR059409A1 (es) 2008-04-09
CA2641769C (en) 2014-02-04
TW200800948A (en) 2008-01-01
JP5616021B2 (ja) 2014-10-29
DK1981872T3 (en) 2017-09-11
JO3389B1 (ar) 2019-03-13
KR101488691B1 (ko) 2015-02-02
AR104288A2 (es) 2017-07-12
WO2007090859A1 (en) 2007-08-16
US20070281971A1 (en) 2007-12-06
CN101379057B (zh) 2013-02-13
IL193103A0 (en) 2009-02-11
CA2641769A1 (en) 2007-08-16
LT1981872T (lt) 2017-09-11
PE20110120A1 (es) 2011-03-08
EP1981872B1 (en) 2017-06-21
IL193103A (en) 2013-06-27
CN101379057A (zh) 2009-03-04
PE20071249A1 (es) 2008-01-16

Similar Documents

Publication Publication Date Title
NO20083425L (no) Ravsyre salt av bifenyl-2-ylkarbaminsyre 1-[2-(2-kloro-4-{[(R)-2-hydroksy-2-(8-hydroksy-2-okso-1,2-dihydroquinolin-5-yl)etylamino]metyl]}-5-metoksyfenylkarbamoyl)etyl]piperidin-4-yl ester og dens anvendelse for behandling av lungesykdom
AR051003A1 (es) Forma cristalina de un compuesto bifenilo
FR20C1046I1 (fr) Vaccins contre la grippe contenant de l'hémagglutinine et des protéines de matrice
NO20083562L (no) Cannabinoidreseptormodulatorer
EA201100621A1 (ru) Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
BRPI0906104A2 (pt) "derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto"
ECSP10010265A (es) Sales farmaceuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8 dihidro-9h-purin-9-il)propil](3-morfolin-4 ilpropil)amino]metil}fenil)
MX2010004501A (es) Inhibidor de la proteina de activacion de 5-lipoxigenasa (plap).
AR075204A1 (es) Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
NO20092694L (no) CRTH2 antagonister
DK1939204T3 (da) Kondenseret heterocyklisk derivat, medicinalsammensætning indeholdende samme og medicinsk anvendelse deraf
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
NO20054180D0 (no) Behandling av bakterielle sykdommer i andedrettsorganene ved lokal tilforsel av fluorkinoloner
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
NO20081081L (no) Nytt salt II
NO20081079L (no) Nytt salt III
IL205981A0 (en) 15,16-METHYLENE-17-HYDROXY-19-NOR-21-CARBOXYLIC ACID ã?-LACTONE DERIVATIVE , USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE
DK2119700T3 (da) Benzylaminderivat eller farmaceutisk acceptabelt syreadditionssalt heraf og anvendelse heraf til medicinske formål
ITMO20050165A1 (it) ''dispositivo medico chirurgico per l'intubazione endotracheale o simil''.
CL2010001489A1 (es) Compuestos derivados de isoquinolinas mediadores de rho-quinasa; composición farmacéutica que comprende dichos compuestos; uso en el tratamiento o prevención de la hipertensión, hipertensión pulmonar, insuficiencia cardíaca, epoc, diabetes, enfermedades autoinmunes, sida, entre otras.
CN300747122S (zh) 药品包装盒(999枇杷露)
SE0400267D0 (sv) Bildskärm/datamonitor med minst 3 st bildrutor
TH124704A (th) สารประกอบและองค์ประกอบทางเภสัชกรรม สำหรับรักษาการติดเชื้อไวรัส

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: THERAVANCE BIOPHARMA R&D IP, US